

## **NATURE publishes encouraging data on DUNP19 receptors role in cancer growth**

- **Prestigious scientific journal Nature releases new data on LRRC15 role in multiple cancers**
- **Article demonstrates that TGF $\beta$ -dependent LRRC15+ tumor stroma play key role in tumour growth**
- **RAD's DUNP19 targets LRRC15 on cancer cells and the surrounding fibroblasts**

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Dr. Shannon J. Turley and her team of more than 30 scientists published an authoritative analysis of the role of LRRC15 in cancer growth. The report was published by prestigious scientific journal Nature on 28 September 2022. The Turley team showed that the LRRC15 proteins on cancer associated fibroblasts (CAFs) are essential for protecting tumour cells from the immune system, and are thus essential for allowing tumours to grow. The report is available here [www.nature.com/articles/s41586-022-05272-1](https://www.nature.com/articles/s41586-022-05272-1).

The research team downgraded the expression of the LRRC15 protein in aggressive tumour cells by using a very elegant knock out mouse model they recently developed.

Radiopharm Theranostics plans to replicate their work in the clinic with a monoclonal antibody against LRRC15 developed by H. David Ulmert, MD, PhD, and colleagues. That antibody, called "DUNP19", will be labelled with a high energy radioactive isotope. Radiolabelled DUNP19 (RAD 502) should kill the tumour cells directly, and perhaps as importantly, the surrounding cells in the tumour microenvironment (TME) that protects the cancer from being attacked by the immune system.

The publication in Nature significantly strengthens already robust assessments of LRRC15 as a biomarker for aggressive malignancies.

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

**For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

**ASX ANNOUNCEMENT  
4 OCTOBER 2022**



Media

Matt Wright

NWR Communications

P: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>